Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

All Conditions

Symptoms and General Pathology

Wounds and Injuries

Digestive System Diseases

Rare Diseases

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Hyperthermia

Fever

Peritoneal Diseases

Gastrointestinal Diseases

Ovarian Cancer

Ovarian Epithelial Cancer

Perioperative data of all the patients posted for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy will be collected prospectively

Hyperthermic intraperitoneal chemotherapy

Sohan L Solanki, MD

Sohan L solanki, MD

Sohan L solanki

Peritoneal carcinomatosis is a common event in the natural history of colorectal and other digestive tract cancers. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) provides a promising therapeutic option for highly selected patients with peritoneal carcinomatosis arising from different malignancies such as colorectal cancer, gastric cancer, ovarian cancer, or peritoneal mesothelioma with improvement of both patient survival and quality of life. CRS, i.e., removal of all visible metastatic abdominal and pelvic disease with peritonectomy along with HIPEC (for 90 min at a temperature of 42º C) and/or early postoperative intraperitoneal chemotherapy (EPIC) in order to eradicate all microscopic metastasis.

CRS with HIPEC is a long and complex procedure with significant blood and fluid loss during debulking, hemodynamic, hematological, and metabolic alterations before and during the HIPEC phase, and even in the early postoperative period, with resultant significant morbidity and mortality. Despite that most of the reported patients are in American Society of Anesthesiologist class I and II, without significant comorbidities or systemic disorder; the morbidity and mortality ranges from 12 to 65% in these procedures, so a well coordinated team of anesthesiologist, surgeons and intensivist and other ancillary services can result in good outcome. This study will see the challenges faced by the team regarding the pathophysiological alterations during the CRS with HIPEC in the perioperative period.

An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

A Prospective Audit of Perioperative Parameters of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC)

Invasive blood pressure will be measured in radial artery in perioperative period and changes from baseline will be recorded in a graphical manner

Body temperature will be measured in degree centigrade by nasopharyngeal temperature probe in perioperative period and changes from baseline will be recorded in a graphical manner

Cardiac output will be measured in perioperative period and changes from baseline will be recorded in a graphical manner

Arterial blood gases will be measured in perioperative period and changes from baseline will be recorded in a graphical manner

Length of stay will be measured in days from admission to discharge in intensive care unit

30 days mortality will be noted if death occurred within this period

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy	NCT02754115	Colorectal Canc... Ovarian Cancer Peritoneal Dise...	Hyperthermic in...	18 Years - 70 Years	Tata Memorial Centre
An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy	NCT02754115	Colorectal Canc... Ovarian Cancer Peritoneal Dise...	Hyperthermic in...	18 Years - 70 Years	Tata Memorial Centre

Spots Global Cancer Trial Database for peritoneal disease